NXGL
NEXGEL, Inc.
Medical - Instruments & Supplies
Market Cap$5M
5Y Perf.-77.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
NXGL vs BFRI vs DERM vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
BFRI
Biofrontera Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$13M
5Y Perf.-99.2%
DERM
Journey Medical Corporation
Drug Manufacturers - Specialty & Generic
Market Cap$104M
5Y Perf.-5.8%
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.62B
5Y Perf.-69.9%
NXGL vs BFRI vs DERM vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NXGL | BFRI | DERM | PRGO |
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $5M | $13M | $104M | $1.62B |
| Revenue (TTM) | $12M | $42M | $56M | $4.18B |
| Net Income (TTM) | $-3M | $-11M | $-9M | $-1.82B |
| Gross Margin | 38.3% | 75.8% | 67.5% | 34.2% |
| Operating Margin | -25.5% | -27.2% | -12.2% | -4.1% |
| Forward P/E | — | — | 69.9x | 5.5x |
| Total Debt | $3M | $6M | $26M | $3.97B |
| Cash & Equiv. | $2M | $6M | $20M | $532M |
NXGL vs BFRI vs DERM vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NXGL
BFRI
DERM
PRGO
| Stock | Dec 21 | May 26 | Return |
|---|---|---|---|
| NEXGEL, Inc. (NXGL) | 100 | 22.7 | -77.3% |
| Biofrontera Inc. (BFRI) | 100 | 0.8 | -99.2% |
| Journey Medical Cor… (DERM) | 100 | 94.2 | -5.8% |
| Perrigo Company plc (PRGO) | 100 | 30.1 | -69.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NXGL vs BFRI vs DERM vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NXGL and DERM are tied at the top with 2 categories each — the right choice depends on your priorities. Journey Medical Corporation is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. PRGO and BFRI also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
NXGL
NEXGEL, Inc.
The Income Pick
NXGL has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- beta 0.85
- Rev growth 112.5%, EPS growth 10.7%, 3Y rev CAGR 77.6%
- Lower volatility, beta 0.85, Low D/E 46.5%, current ratio 2.07x
- Beta 0.85, current ratio 2.07x
Best for: income & stability and growth exposure
BFRI
Biofrontera Inc.
The Momentum Pick
BFRI is the clearest fit if your priority is momentum.
- +58.1% vs NXGL's -77.3%
Best for: momentum
DERM
Journey Medical Corporation
The Long-Run Compounder
DERM is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- -46.6% 10Y total return vs PRGO's -77.7%
- -15.5% margin vs PRGO's -43.5%
- -10.8% ROA vs BFRI's -52.2%, ROIC -56.8% vs -124.3%
Best for: long-term compounding
PRGO
Perrigo Company plc
The Value Play
PRGO is the clearest fit if your priority is value and dividends.
- Lower P/E (5.5x vs 69.9x)
- 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
Best for: value and dividends
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NXGL | 112.5% revenue growth vs DERM's -29.1% |
| Value | PRGO | Lower P/E (5.5x vs 69.9x) |
| Quality / Margins | DERM | -15.5% margin vs PRGO's -43.5% |
| Stability / Safety | NXGL | Beta 0.85 vs DERM's 1.78, lower leverage |
| Dividends | PRGO | 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | BFRI | +58.1% vs NXGL's -77.3% |
| Efficiency (ROA) | DERM | -10.8% ROA vs BFRI's -52.2%, ROIC -56.8% vs -124.3% |
NXGL vs BFRI vs DERM vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2023
FY 2024
FY 2025
NXGL vs BFRI vs DERM vs PRGO — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBFRILAGGINGNXGL
Who Leads Where
BFRI leads in 1 of 6 categories
PRGO leads 1 • DERM leads 1 • NXGL leads 0 • 2 tied
Explore the data ↓NXGLNEXGEL, Inc.
0leads
PRGOPerrigo Company plc
1leads
DERMJourney Medical Corpo…
1leads
BFRIBiofrontera Inc.
1leads
6 Total Categories
CATEGORYLEADERvs DERMvs PRGOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BFRI3/6
Valuation MetricsMultiples, price ratios, and targets
PRGO2/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
DERM4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BFRI leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 358.2x NXGL's $12M. DERM is the more profitable business, keeping -15.5% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, BFRI holds the edge at +36.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NXGLNEXGEL, Inc. | BFRIBiofrontera Inc. | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $12M | $42M | $56M | $4.2B |
| EBITDAEarnings before interest/tax | -$2M | -$11M | -$3M | $58M |
| Net IncomeAfter-tax profit | -$3M | -$11M | -$9M | -$1.8B |
| Free Cash FlowCash after capex | -$3M | -$13M | -$3M | $108M |
| Gross MarginGross profit ÷ Revenue | +38.3% | +75.8% | +67.5% | +34.2% |
| Operating MarginEBIT ÷ Revenue | -25.5% | -27.2% | -12.2% | -4.1% |
| Net MarginNet income ÷ Revenue | -24.7% | -25.3% | -15.5% | -43.5% |
| FCF MarginFCF ÷ Revenue | -21.8% | -32.0% | -4.8% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -0.2% | +36.2% | +1.0% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +27.3% | +100.0% | +5.9% | -56.4% |
BFRI leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
| Metric | NXGLNEXGEL, Inc. | BFRIBiofrontera Inc. | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| Market CapShares × price | $5M | $13M | $104M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $6M | $13M | $109M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.19x | — | -7.04x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 69.93x | 5.53x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 7.43x |
| Price / SalesMarket cap ÷ Revenue | 0.56x | 0.32x | 1.85x | 0.38x |
| Price / BookPrice ÷ Book value/share | 0.64x | — | 5.16x | 0.55x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 11.17x |
PRGO leads this category, winning 2 of 4 comparable metrics.
Profitability & Efficiency
Evenly matched — NXGL and DERM and PRGO each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
DERM delivers a -45.4% return on equity — every $100 of shareholder capital generates $-45 in annual profit, vs $-11 for BFRI. NXGL carries lower financial leverage with a 0.46x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), NXGL scores 4/9 vs DERM's 2/9, reflecting mixed financial health.
| Metric | NXGLNEXGEL, Inc. | BFRIBiofrontera Inc. | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -51.7% | -11.4% | -45.4% | -50.7% |
| ROA (TTM)Return on assets | -26.9% | -52.2% | -10.8% | -19.8% |
| ROICReturn on invested capital | -43.1% | -124.3% | -56.8% | +3.7% |
| ROCEReturn on capital employed | -44.7% | -84.8% | -34.2% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.46x | 0.59x | 1.28x | 1.35x |
| Net DebtTotal debt minus cash | $1M | -$231,000 | $5M | $3.4B |
| Cash & Equiv.Liquid assets | $2M | $6M | $20M | $532M |
| Total DebtShort + long-term debt | $3M | $6M | $26M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | -40.04x | -69.93x | -1.52x | -7.20x |
Evenly matched — NXGL and DERM and PRGO each lead in 3 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
DERM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DERM five years ago would be worth $5,337 today (with dividends reinvested), compared to $130 for BFRI. Over the past 12 months, BFRI leads with a +58.1% total return vs NXGL's -77.3%. The 3-year compound annual growth rate (CAGR) favors DERM at 45.4% vs BFRI's -54.2% — a key indicator of consistent wealth creation.
| Metric | NXGLNEXGEL, Inc. | BFRIBiofrontera Inc. | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -67.2% | +58.6% | -31.9% | -13.6% |
| 1-Year ReturnPast 12 months | -77.3% | +58.1% | -26.3% | -52.0% |
| 3-Year ReturnCumulative with dividends | -59.9% | -90.4% | +207.3% | -58.1% |
| 5-Year ReturnCumulative with dividends | -83.1% | -98.7% | -46.6% | -60.3% |
| 10-Year ReturnCumulative with dividends | -83.1% | -98.7% | -46.6% | -77.7% |
| CAGR (3Y)Annualised 3-year return | -26.3% | -54.2% | +45.4% | -25.2% |
DERM leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NXGL and BFRI each lead in 1 of 2 comparable metrics.
Risk & Volatility
NXGL is the less volatile stock with a 0.85 beta — it tends to amplify market swings less than DERM's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BFRI currently trades 96.6% from its 52-week high vs NXGL's 20.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NXGLNEXGEL, Inc. | BFRIBiofrontera Inc. | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.85x | 1.63x | 1.78x | 1.21x |
| 52-Week HighHighest price in past year | $2.97 | $1.19 | $9.55 | $28.44 |
| 52-Week LowLowest price in past year | $0.56 | $0.54 | $4.31 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +20.0% | +96.6% | +53.1% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 45.1 | 63.6 | 39.7 | 53.1 |
| Avg Volume (50D)Average daily shares traded | 371K | 121K | 231K | 3.3M |
Evenly matched — NXGL and BFRI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: DERM as "Buy", PRGO as "Hold". Consensus price targets imply 209.1% upside for PRGO (target: $36) vs 131.8% for DERM (target: $12). PRGO is the only dividend payer here at 9.82% yield — a key consideration for income-focused portfolios.
| Metric | NXGLNEXGEL, Inc. | BFRIBiofrontera Inc. | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Hold |
| Price TargetConsensus 12-month target | — | — | $11.75 | $36.20 |
| # AnalystsCovering analysts | — | — | 3 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +9.8% |
| Dividend StreakConsecutive years of raises | — | — | — | 10 |
| Dividend / ShareAnnual DPS | — | — | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BFRI leads in 1 of 6 categories (Income & Cash Flow). PRGO leads in 1 (Valuation Metrics). 2 tied.
Best OverallBiofrontera Inc. (BFRI)Leads 1 of 6 categories
Loading custom metrics...
NXGL vs BFRI vs DERM vs PRGO: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is NXGL or BFRI or DERM or PRGO a better buy right now?
For growth investors, NEXGEL, Inc.
(NXGL) is the stronger pick with 112. 5% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NXGL or BFRI or DERM or PRGO?
Over the past 5 years, Journey Medical Corporation (DERM) delivered a total return of -46.
6%, compared to -98. 7% for Biofrontera Inc. (BFRI). Over 10 years, the gap is even starker: DERM returned -46. 6% versus BFRI's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NXGL or BFRI or DERM or PRGO?
By beta (market sensitivity over 5 years), NEXGEL, Inc.
(NXGL) is the lower-risk stock at 0. 85β versus Journey Medical Corporation's 1. 78β — meaning DERM is approximately 111% more volatile than NXGL relative to the S&P 500. On balance sheet safety, NEXGEL, Inc. (NXGL) carries a lower debt/equity ratio of 46% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
04Which is growing faster — NXGL or BFRI or DERM or PRGO?
By revenue growth (latest reported year), NEXGEL, Inc.
(NXGL) is pulling ahead at 112. 5% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Biofrontera Inc. grew EPS 100. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, NXGL leads at 77. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NXGL or BFRI or DERM or PRGO?
Biofrontera Inc.
(BFRI) is the more profitable company, earning -25. 3% net margin versus -37. 8% for NEXGEL, Inc. — meaning it keeps -25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -40. 9% for NXGL. At the gross margin level — before operating expenses — BFRI leads at 75. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is NXGL or BFRI or DERM or PRGO more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
5x forward P/E versus 69. 9x for Journey Medical Corporation — 64. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.
07Which pays a better dividend — NXGL or BFRI or DERM or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. NXGL, BFRI, DERM do not pay a meaningful dividend and should not be held primarily for income.
08Is NXGL or BFRI or DERM or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
21), 9. 8% yield). Journey Medical Corporation (DERM) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -77. 7%, DERM: -46. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between NXGL and BFRI and DERM and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NXGL is a small-cap high-growth stock; BFRI is a small-cap quality compounder stock; DERM is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while NXGL, BFRI, DERM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(NXGL: -0.2% · BFRI: 36.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.